LS11

Phase 2Small molecule

LLight Sciences Oncology

LS11 is one of 50 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Plexiform NeurofibromaActive, not recruiting

GliomaPhase 2

Active, not recruiting

Plexiform NeurofibromaPhase 1

Active, not recruiting

Competition

Competitive Landscape

394 competitors in Glioma

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

2 2

Bicnu

MMelissa K Accordino

Phase 3

7 3

Vepesid

AAvyxa

Phase 3

4 4

Photofrin

PPinnacle Biologics Inc.

Phase 3

2 5

Ifex

BBaxter Healthcare Corporation

Phase 3

1 6

Rayos

RRoxane Laboratories

Phase 3

1 7

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 8

Velban

EEastern Cooperative Oncology Group

Phase 3

1 9

Modeyso

CChimerix

Phase 3

3 10

Selumetinib /m2

NNational Cancer Institute (NCI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioma1 trial

Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma

Completed·LLight Sciences Oncology·Phase 2·NCT00409214·18 enrolled

Plexiform Neurofibroma1 trial

Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas

Terminated·—·Phase 1·NCT00716469·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LS11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LS11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LS11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Light Sciences Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLight Sciences Oncology

LS11

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioma1 trial

Plexiform Neurofibroma1 trial

References

Drug Info

Quick Facts

Related News